Associated Genetic Biomarkers
GATA binding protein 3 (GATA3) is a gene that encodes a transcription factor protein that contains two zinc fingers. The protein functions in immune regulation by regulating T-cell development. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as biliary tract cancer, breast cancer, and intestinal cancer.
GATA3 is altered in 3.67% of all cancers with breast invasive ductal carcinoma, invasive breast carcinoma, lung adenocarcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in GATA3 are GATA3 Mutation (1.33%), GATA3 Amplification (0.47%), GATA3 Loss (0.40%), GATA3 X308_splice (0.43%), and GATA3 M293K (0.07%) .
GATA3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with GATA3 status in the inclusion eligibility criteria most commonly target bladder carcinoma, breast carcinoma, colorectal carcinoma, head and neck carcinoma, and lymphoma .
The most frequent alterations to serve as inclusion eligibility criteria are GATA3 Loss and GATA3 Mutation .
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials with GATA3 as an inclusion criteria .
Significance of GATA3 in Diseases
Breast Carcinoma +
Bladder Carcinoma +
Anaplastic Astrocytoma +
Non-Small Cell Lung Carcinoma +
GATA3 is altered in 2.11% of non-small cell lung carcinoma patients .
GATA3 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Colorectal Carcinoma +
Malignant Solid Tumor +
Ovarian Carcinoma +
Head And Neck Carcinoma +
GATA3 is altered in 1.08% of head and neck carcinoma patients .
GATA3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Pancreatic Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.